» Articles » PMID: 23151972

Mental Health Disorders Influence Admission Rates for Pain in Children with Sickle Cell Disease

Overview
Date 2012 Nov 16
PMID 23151972
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patients with sickle cell disease (SCD) experience a broad range of mental health disorders placing them at risk for more complicated hospitalizations for pain. The current study examined the impact of mental health disorders on admission rates and hospital length of stay (LOS) for vaso-occlusive pain events (VOE) in pediatric patients with SCD.

Procedure: Patients (5-18 years old) with a primary discharge diagnosis of SCD with crisis were acquired through the Pediatric Health Information System and categorized by history of mental health disorders (mood disorder, anxiety disorder, disruptive behavior disorder, and substance use disorder). Using a retrospective cohort design, hospital admission rates for VOE were examined as the primary outcome and LOS as a secondary outcome.

Results: A total of 5,825 patients accounted for 23,561 admissions for SCD with crisis with approximately 8% of the patients having a mental health diagnosis. Longer LOS was found among patients with a history of any mental health diagnosis (P < 0.0001) and within the mood disorder (P < 0.0001), anxiety disorder (P < 0.0001), and substance use disorder (P = 0.01) subtypes. Hospital admissions rates for VOE were higher among patients with a history of any mental health diagnosis (P < 0.0001) and within the mood disorder (P < 0.0001), anxiety disorder (P < 0.0001), disruptive behavior disorder (P = 0.002), and substance use disorder (P < 0.0001) subtypes.

Conclusions: Pediatric patients with SCD and a history of a mental health diagnosis have longer LOS and higher admission rates for management of VOE. Ultimately, these findings suggest that mental health pose a challenge to the management of sickle cell pain.

Citing Articles

Factors of well-being of youth with complex medical conditions from the experience of hospitalization and convalescence: A pilot study.

Munoz-Violant S, Violant-Holz V, Rodriguez M PLoS One. 2023; 18(5):e0285213.

PMID: 37141278 PMC: 10159209. DOI: 10.1371/journal.pone.0285213.


Subanesthetic ketamine: the way forward for pain management in sickle cell disease patients?.

Nobrega R, Carullo V, Thein S, Quezado Z Expert Rev Hematol. 2022; 15(10):887-891.

PMID: 36191299 PMC: 9985469. DOI: 10.1080/17474086.2022.2131523.


Examining resilience of individuals living with sickle cell disease in the COVID-19 pandemic.

Buscetta A, Abdallah K, Floyd K, Wossenseged F, Conn C, Ramirez H BMC Psychol. 2022; 10(1):156.

PMID: 35725582 PMC: 9207426. DOI: 10.1186/s40359-022-00862-0.


Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA.

Smeltzer M, Howell K, Treadwell M, Preiss L, King A, Glassberg J BMJ Open. 2021; 11(11):e050880.

PMID: 34789492 PMC: 8601067. DOI: 10.1136/bmjopen-2021-050880.


Pain-Related Injustice Appraisals in Youth with Sickle Cell Disease: A Preliminary Investigation.

Miller M, Rumble D, Hirsh A, Vervoort T, Crosby L, Madan-Swain A Pain Med. 2021; 22(10):2207-2217.

PMID: 33723587 PMC: 8677454. DOI: 10.1093/pm/pnab001.